Search Results - "Peter, Hillmen"

Thrombosis in paroxysmal nocturnal hemoglobinuria by Hill, Anita, Kelly, Richard J., Hillmen, Peter

“…The most frequent and feared complication of paroxysmal nocturnal hemoglobinuria (PNH) is thrombosis. Recent research has demonstrated that the complement and…”
Get full text

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL by Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillermo, Döhner, Hartmut, Hillmen, Peter, Keating, Michael, Montserrat, Emili, Chiorazzi, Nicholas, Stilgenbauer, Stephan, Rai, Kanti R., Byrd, John C., Eichhorst, Barbara, O'Brien, Susan, Robak, Tadeusz, Seymour, John F., Kipps, Thomas J.

“…The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad…”
Get full text

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial by Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech

“…Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy…”
Get full text

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis by Socié, Gérard, Caby‐Tosi, Marie‐Pierre, Marantz, Jing L., Cole, Alexander, Bedrosian, Camille L., Gasteyger, Christoph, Mujeebuddin, Arshad, Hillmen, Peter, Vande Walle, Johan, Haller, Hermann

“…Summary Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS)…”
Get full text

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia by Seymour, John F, Kipps, Thomas J, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Gerecitano, John, Robak, Tadeusz, De la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Humerickhouse, Rod, Punnoose, Elizabeth A, Li, Yan, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, Kater, Arnon P

“…In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in…”
Get full text

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study by Hillmen, Peter, Rawstron, Andy C, Brock, Kristian, Muñoz-Vicente, Samuel, Yates, Francesca J, Bishop, Rebecca, Boucher, Rebecca, MacDonald, Donald, Fegan, Christopher, McCaig, Alison, Schuh, Anna, Pettitt, Andrew, Gribben, John G, Patten, Piers E M, Devereux, Stephen, Bloor, Adrian, Fox, Christopher P, Forconi, Francesco, Munir, Talha

“…The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate…”
Get full text

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study by Kater, Arnon P, Seymour, John F, Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W, Owen, Carolyn, Verdugo, Maria, Wu, Jenny, Punnoose, Elizabeth A, Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, Kipps, Thomas J

“…The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab…”
Get full text

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells by Kwok, Marwan, Davies, Nicholas, Agathanggelou, Angelo, Smith, Edward, Oldreive, Ceri, Petermann, Eva, Stewart, Grant, Brown, Jeff, Lau, Alan, Pratt, Guy, Parry, Helen, Taylor, Malcolm, Moss, Paul, Hillmen, Peter, Stankovic, Tatjana

“…TP53 and ataxia telangiectasia mutated (ATM) defects are associated with genomic instability, clonal evolution, and chemoresistance in chronic lymphocytic…”
Get full text

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL by Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P., Cashen, Amanda F., Weaver, David T., Kelly, Virginia M., Turnbull, Barry, Stilgenbauer, Stephan

“…Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and γ (PI3K-δ,γ) being developed for treatment of hematologic…”
Get full text

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study by Kater, Arnon P, Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R, Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Seymour, John F

“…In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with…”
Get full text

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors by Hillmen, Peter, Horneff, Regina, Yeh, Michael, Kolev, Martin, Deschatelets, Pascal

“…Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and potentially life-threatening hematologic disorder caused by a somatic mutation in a relevant portion of…”
Get full text

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab by Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.

“…Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase…”
Get full text

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines by Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillaume, Döhner, Hartmut, Hillmen, Peter, Keating, Michael J., Montserrat, Emili, Rai, Kanti R., Kipps, Thomas J.

“…Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by…”
Get full text

Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia by HILLMEN, Peter, SKOTNICKI, Aleksander B, ROBAK, Tadeusz, JAKSIC, Branimir, DMOSZYNSKA, Anna, JINGYANG WU, SIRARD, Cynthia, MAYER, Jiri

“…We conducted a randomized trial to evaluate the efficacy and safety of intravenous alemtuzumab compared with chlorambucil in first-line treatment of chronic…”
Get full text

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials by Brown, Jennifer R, Moslehi, Javid, O'Brien, Susan, Ghia, Paolo, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D, Fraser, Graeme, Rule, Simon, Kipps, Thomas J, Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C, Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F, Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle, Burger, Jan A

“…The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been…”
Get full text

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study by O'Brien, Susan, Prof, Jones, Jeffrey A, MD, Coutre, Steven E, Prof, Mato, Anthony R, MD, Hillmen, Peter, Prof, Tam, Constantine, MD, Österborg, Anders, Prof, Siddiqi, Tanya, MD, Thirman, Michael J, MD, Furman, Richard R, MD, Ilhan, Osman, Prof, Keating, Michael J, Prof, Call, Timothy G, MD, Brown, Jennifer R, MD, Stevens-Brogan, Michelle, MSc, Li, Yunfeng, PhD, Clow, Fong, ScD, James, Danelle F, MD, Chu, Alvina D, MD, Hallek, Michael, Prof, Stilgenbauer, Stephan, Prof

“…Summary Background The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion…”
Get full text

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial by Zelenetz, Andrew D, Prof, Barrientos, Jacqueline C, MD, Brown, Jennifer R, MD, Coiffier, Bertrand, Prof, Delgado, Julio, MD, Egyed, Miklós, Prof, Ghia, Paolo, MD, Illés, Árpád, Prof, Jurczak, Wojciech, MD, Marlton, Paula, MBBS, Montillo, Marco, MD, Morschhauser, Franck, Prof, Pristupa, Alexander S, MD, Robak, Tadeusz, Prof, Sharman, Jeff P, MD, Simpson, David, MBChB, Smolej, Lukáš, MD, Tausch, Eugen, MD, Adewoye, Adeboye H, MD, Dreiling, Lyndah K, MD, Kim, Yeonhee, PhD, Stilgenbauer, Stephan, Prof, Hillmen, Peter, Prof

“…Summary Background Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia…”
Get full text

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 by Barr, Paul M, Robak, Tadeusz, Owen, Carolyn, Tedeschi, Alessandra, Bairey, Osnat, Bartlett, Nancy L, Burger, Jan A, Hillmen, Peter, Coutre, Steven, Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Li, Jianyong, Simpson, David, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Styles, Lori, James, Danelle, Kipps, Thomas J, Ghia, Paolo

“…Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of…”
Get full text

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial by Hillmen, Peter, Prof, Robak, Tadeusz, MD, Janssens, Ann, MD, Babu, K Govind, MD, Kloczko, Janusz, MD, Grosicki, Sebastian, MD, Doubek, Michael, MD, Panagiotidis, Panagiotis, MD, Kimby, Eva, MD, Schuh, Anna, MD, Pettitt, Andrew R, MRCPath, Boyd, Thomas, MD, Montillo, Marco, MD, Gupta, Ira V, MD, Wright, Oliver, BSc, Dixon, Iestyn, BSc, Carey, Jodi L, RN BSN, Chang, Chai-Ni, MS, Lisby, Steen, MD, McKeown, Astrid, PhD, Offner, Fritz, MD

“…Summary Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based…”
Get full text

COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience by Pike, Alexandra, Muus, Petra, Munir, Tahla, Mitchell, Lindsay, Arnold, Louise, Riley, Kathryn, Houghton, Nicola, Forrest, Briony, Gachev, Jeanifer, Hillmen, Peter, Griffin, Morag

Get full text